Peripheral Neuropathy — Written Clinical Reasoning

Part A — Diagnostic approach and classification

The first discipline is to classify the neuropathy before generating a differential. This patient has two superimposed patterns — a chronic distal symmetric polyneuropathy (the 3-year burning numbness, stocking-distribution sensory loss, absent ankle reflexes, and painless foot ulcer) and a subacute mononeuritis multiplex (the 6-week history of painful, asymmetric, stepwise involvement of the right peroneal nerve and the right ulnar nerve, with weight loss and night sweats). [1]

The chronic distal symmetric pattern is, by far, most likely diabetic distal symmetric polyneuropathy (DSPN) in a man with a 15-year history of type 2 diabetes and an HbA1c of 78 mmol per mol — the poor glycaemic control, the length-dependent sensory loss, the absent ankle reflexes, and the painless foot ulcer (the classic triad of neuropathy, ischaemia, and deformity) are all consistent [1].

The superimposed subacute mononeuritis multiplex is the concerning new development. Mononeuritis multiplex — painful, asymmetric, stepwise involvement of multiple individual named nerves — is the signature of vasculitic neuropathy until proven otherwise [4], and the systemic symptoms of weight loss and night sweats raise the possibility of an underlying systemic vasculitis or a paraproteinaemic process. The small IgM kappa paraprotein adds a further layer — it may be an incidental MGUS, or it may be relevant (anti-MAG neuropathy is typically a chronic distal demyelinating sensory neuropathy, not a mononeuritis multiplex, but paraproteinaemic disease and vasculitis can coexist, and cryoglobulinaemic vasculitis is classically associated with a paraprotein and hepatitis C).

Key point: Never assume that all neuropathy in a diabetic patient is due to diabetes. Up to 10 to 50 per cent of neuropathy in diabetics has an alternative or additional cause. The new, subacute, asymmetric, painful, stepwise pattern in this patient demands investigation for vasculitis and paraproteinaemic disease. [1]

Part B — Investigation pathway

Step 1 — Nerve conduction studies and EMG

The NCS is the gatekeeper. I would expect it to show two patterns: a background of a distal symmetric axonal sensorimotor neuropathy (reduced sural and peroneal amplitudes with preserved conduction velocity — consistent with diabetic DSPN), and superimposed axonal mononeuropathies of the right peroneal and ulnar nerves (reduced amplitudes in the affected nerves, with evidence of active denervation on needle EMG). The axonal pattern in the mononeuropathies, combined with the asymmetric, stepwise clinical evolution, is consistent with vasculitic nerve infarction rather than entrapment or compression. If the paraprotein proves to be anti-MAG, there may also be a distal demyelinating component with markedly prolonged distal latencies. [1]

Step 2 — Blood panels

First-line (every patient with neuropathy) — fasting glucose and HbA1c (already known), vitamin B12 with methylmalonic acid and homocysteine (his B12 of 220 pmol per L is borderline, and he should have metabolites checked to exclude functional deficiency, particularly if he is on metformin), full blood count, urea and electrolytes, liver function, and thyroid function [2].

Vasculitic and paraproteinaemic screen (the key panel for this patient) — ANA and extractable nuclear antigens, ANCA (MPO and PR3), rheumatoid factor, complements C3 and C4, cryoglobulins (sent and transported at 37 degrees to prevent precipitation), hepatitis B and C serology, HIV, lactate dehydrogenase, and serum protein electrophoresis with immunofixation and serum free light chains (already showing a small IgM kappa band — the ratio and bone marrow assessment will determine significance). [1]

Targeted additional tests — anti-MAG antibody (given the IgM paraprotein), and a full myeloma and amyloid screen if the paraprotein proves significant (serum free light chain ratio, urine Bence Jones protein, beta-2 microglobulin, calcium, and a bone marrow biopsy if indicated). [1]

Step 3 — CSF, genetics, and biopsy

A lumbar puncture would be considered if there is a possibility of CIDP (which can coexist with diabetes and a paraprotein) — cytoalbuminologic dissociation would support a demyelinating component. However, the axonal mononeuritis multiplex pattern is not typical of CIDP. [1]

A sural nerve biopsy is indicated in this patient to confirm the suspected vasculitic neuropathy, because the result will change management (initiation of immunosuppression) and because less invasive tests may not be diagnostic [4]. The biopsy would show vasculitis of the vasa nervorum (fibrinoid necrosis of the vessel wall with inflammatory infiltrate), asymmetric fibre loss across fascicles, and evidence of ischaemic injury (axonal degeneration with regenerating clusters). The biopsy should sample both a sensory nerve (sural) and, ideally, a nearby muscle (peroneus brevis via the same incision), to increase the diagnostic yield. The contralateral sural nerve should be biopsied if the ipsilateral is abnormal on NCS but the biopsy is non-diagnostic.

Genetic testing is not indicated — the phenotype is not that of a hereditary neuropathy (no foot deformity, no family history, subacute asymmetric evolution). [1]

Part C — Likely dual pathology

My working diagnosis is: [1]

1. Diabetic distal symmetric polyneuropathy — the background chronic length-dependent neuropathy, with the painless foot ulcer reflecting the triad of neuropathy, peripheral arterial disease (he is a smoker), and foot deformity.
2. Superimposed vasculitic neuropathy (mononeuritis multiplex) — the subacute, painful, asymmetric, stepwise peroneal and ulnar mononeuropathies, likely from a systemic vasculitis (given the weight loss and night sweats) or possibly a cryoglobulinaemic vasculitis associated with the IgM paraprotein and hepatitis C. [1]

The IgM kappa paraprotein is most likely an incidental MGUS, but the possibility of a pathogenic role (anti-MAG, cryoglobulinaemia, or underlying lymphoproliferative disease) must be excluded. [1]

Part D — Integrated management

Treat the underlying cause

For the vasculitic neuropathy (the active, dangerous process) — once the biopsy confirms vasculitis, I would commence urgent high-dose immunosuppression: intravenous methylprednisolone 1 g daily for 3 to 5 days followed by oral prednisolone 1 mg per kg per day, with cyclophosphamide (intravenous pulses, 15 mg per kg every 2 to 4 weeks, dose-adjusted for renal function and age) for severe or rapidly progressive disease, followed by maintenance immunosuppression with azathioprine or methotrexate for 18 to 24 months after remission [4]. Pneumocystis prophylaxis (co-trimoxazole), gastric protection (PPI), and bone protection (calcium and vitamin D) should be prescribed. If the vasculitis is ANCA-associated, rituximab is an alternative induction agent.

For the diabetic DSPN — glycaemic control is the only disease-modifying intervention, and it is most effective when achieved early and sustained; in this patient with poor control (HbA1c 78 mmol per mol), intensification of therapy is essential, though the effect on established neuropathy is limited in type 2 diabetes. Multimodal cardiovascular risk factor management — blood pressure, lipids, and smoking cessation (smoking worsens both the neuropathy and the peripheral arterial disease threatening his foot) — is equally important [1].

For the paraprotein — if it is confirmed as anti-MAG neuropathy, rituximab may be considered (variable response); if it is an incidental MGUS, surveillance; if it reflects underlying myeloma or lymphoma, disease-specific therapy. [1]

Control neuropathic pain

The burning pain of the diabetic DSPN warrants first-line therapy with a gabapentinoid (pregabalin 75 mg twice daily, titrate to 150 to 300 mg twice daily) or duloxetine 30 mg daily then 60 mg daily, or a tricyclic antidepressant (amitriptyline 10 to 25 mg at night) [5]. The choice is guided by comorbidity — duloxetine if he is depressed or anxious, amitriptyline if he has insomnia, pregabalin if he has anxiety or needs a rapid titration. I would avoid strong opioids long-term. The acute pain of the vasculitic neuropathy may require short-term opioid analgesia and will improve with immunosuppression.

Prevent complications

Foot care is critical given the existing ulcer. The ulcer requires urgent podiatric and vascular assessment — debridement, offloading (total contact cast or offloading boot), assessment of peripheral arterial disease (ankle-brachial index, duplex, and angiography if indicated), wound swab and culture, and antibiotic therapy for infection. The ulcer precedes 85 per cent of diabetes-related amputations, and most are preventable with aggressive early management. [1]

Falls prevention — the sensory ataxia and right foot drop increase his fall risk. I would arrange an ankle-foot orthosis for the foot drop, a home safety assessment by occupational therapy, and physiotherapy for gait retraining and strengthening. [1]

Monitoring — clinical review of the vasculitic neuropathy response (improvement in pain, stabilisation of deficits, and prevention of new mononeuropathies), monitoring of the immunosuppression (full blood count, renal function, urinalysis for cyclophosphamide-induced haemorrhagic cystitis, glucose with steroids), and ongoing surveillance for transformation of the MGUS. [1]

Part E — Discussing the key decisions

Examiner: "How do you distinguish a diabetic mononeuritis multiplex from a vasculitic mononeuritis multiplex?" [1]

Clinically they can overlap, as both can produce painful, asymmetric, stepwise mononeuropathies in a diabetic. Diabetic mononeuritis multiplex is thought to be a microvasculitic process and may respond to the same immunosuppression. However, the systemic symptoms (weight loss, night sweats), the presence of a paraprotein, and the rapid evolution in this patient favour an independent systemic vasculitis, and a sural nerve biopsy is essential to confirm the diagnosis and guide the intensity and duration of immunosuppression. The biopsy may also reveal cryoglobulinaemic vasculitis (with intravascular deposits) if that is the underlying mechanism. [1]

Examiner: "What is the significance of the IgM paraprotein, and how do you investigate it further?" [1]

An IgM paraprotein in the setting of a neuropathy raises several possibilities: an incidental MGUS (most common), anti-MAG neuropathy (a chronic distal demyelinating sensory neuropathy with sensory ataxia and tremor, which does not fit the mononeuritis multiplex pattern here), cryoglobulinaemic vasculitis (classically associated with hepatitis C and an IgM kappa paraprotein with rheumatoid factor activity — which would fit this patient and warrants urgent cryoglobulin and hepatitis C testing), or underlying lymphoproliferative disease (Waldenstrom macroglobulinaemia). Further investigation includes anti-MAG antibody, cryoglobulins, hepatitis C serology, rheumatoid factor, serum viscosity, serum free light chain ratio, a CT of the chest, abdomen and pelvis for lymphadenopathy, and a bone marrow biopsy if the paraprotein is significant or the haematology parameters are abnormal. [1]

Examiner: "Why is a nerve biopsy justified in this patient?" [1]

A sural nerve biopsy carries a risk of permanent sensory loss in the biopsied nerve distribution, wound infection, and delayed healing, and the AAN practice parameter notes insufficient evidence for routine biopsy in distal symmetric polyneuropathy [2]. However, in suspected vasculitic neuropathy, the biopsy is the definitive diagnostic test, the result directly changes management (initiation of potentially toxic immunosuppression), and the risk-benefit balance favours biopsy. Combining nerve and muscle biopsy (the combined sural-peroneus brevis biopsy) increases the diagnostic yield for vasculitis. The biopsy should be performed on the clinically affected side, and the contralateral nerve sampled if the first is non-diagnostic.

Examiner: "What is the prognosis of his diabetic neuropathy, and can it be reversed?" [1]

Established nerve fibre loss in diabetic DSPN is largely irreversible. However, glycaemic control and cardiovascular risk factor management slow progression (the effect is strongest in type 1 diabetes and more modest in type 2), pain and autonomic symptoms can be managed pharmacologically, and the complications (ulceration, Charcot neuroarthropathy, falls) are preventable with structured foot care and rehabilitation. The vasculitic neuropathy, by contrast, may improve substantially with immunosuppression if treated early, but delay leads to irreversible nerve infarction — hence the urgency. [1]